Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.

@article{Uttarkar2016TargetingAM,
  title={Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.},
  author={Sagar Uttarkar and Emilie Dass{\'e} and Anna Coulibaly and Simone Steinmann and A. F. Jakobs and Caroline Schomburg and Amke Trentmann and Joachim Jose and Peter Schlenke and Wolfgang E. Berdel and Thomas J{\"u}rgen Schmidt and Carsten M{\"u}ller-Tidow and Jon Frampton and Karl-Heinz Klempnauer},
  journal={Blood},
  year={2016},
  volume={127 9},
  pages={1173-82}
}
The transcription factor Myb plays a key role in the hematopoietic system and has been implicated in the development of leukemia and other human cancers. Inhibition of Myb is therefore emerging as a potential therapeutic strategy for these diseases. However, because of a lack of suitable inhibitors, the feasibility of therapeutic approaches based on Myb inhibition has not been explored. We have identified the triterpenoid Celastrol as a potent low-molecular-weight inhibitor of the interaction… CONTINUE READING